← All verdicts
Verdict

Data Unavailable

Every analyzed stock in Data Unavailable — 2,921 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Data Unavailable" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 3.1% below its 1-year high (as of 2026-09-16). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 7.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Proxy: price-to-book ≤ 1.2 (undervalued band has no point-in-time history yet) · bought the day of the annual report, held 12 months
Probable Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +12.6 pts (1,427 entries, 311 companies, very unlikely to be luck). 50% of entries beat the S&P; 25% beat it by 30 points or more; 30% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +10.9 pts.
+12.6 ptsvs S&P, average
50%beat the S&P
25%up 30+ pts vs S&P
30%down 20+ pts vs S&P
+14.0 ptsvs small caps, 12 mo
−15.1 pts 2019worst year to buy ?
6.1luck check ?
Does the holding period matter?3 mo: +2.3 pts 49% beat6 mo: +4.6 pts 49% beat12 mo: +12.6 pts 50% beat24 mo: +21.8 pts 46% beat3 yr, per yr: +1.3 pts 40% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today1,245+7.9 pts t 4.6+10.1 pts
Sell-off (S&P ≥10% off high)182+44.5 pts t 4.0+40.7 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing466+13.0 pts t 4.0−2.2 pts
Energy126+7.4 pts t 1.2−7.8 pts
Other115+8.4 pts t 1.8+3.8 pts
Tech hardware & semis113+10.9 pts t 1.6+2.3 pts
Services96+11.9 pts t 2.7+12.2 pts
Retail & consumer87+17.2 pts t 2.1+10.2 pts
Finance & real estate72−1.7 pts t -0.5−2.4 pts
Utilities65+5.6 pts t 0.6−1.2 pts
Construction53+13.2 pts t 1.7−2.4 pts
Biotech & pharma44+47.1 pts t 1.6+10.0 pts
Telecom & media43+14.0 pts t 0.7−6.3 pts
Software & IT services35+39.9 pts t 1.8+1.2 pts

Holds up out of sample? Before 2018: +10.7 pts (n 629, t 6.0). From 2018: +14.0 pts (n 798, t 4.1). Same sign in both halves.

Year2010201120122013201420152016201720182019202020212022202320242025
vs S&P+13 pts+5 pts+14 pts+18 pts−4 pts−4 pts+22 pts+12 pts−3 pts−15 pts+87 pts+8 pts+17 pts−9 pts−7 pts+15 pts
n254310610178841118178991297276108121115

Read the research behind this screen: Price-to-book still sorts, across all sizes → · Test your own combination in the Screen Lab →

Our model values are recomputed daily but were never stored historically, so this band cannot be backtested honestly yet. Daily snapshots began 2026-09-10; a true record accrues from there. Until then the nearest tested cousin is shown — cheap on book value — and labelled as a proxy. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
CEF
Sprott Physical Gold & Silver Trust
Valuation N/A
Financial Services Risk 51 · Elevated
Price$44.15
Model IV—
P/IV—
Limited data — see page
CEG
Constellation Energy Corp
Valuation N/A
Utilities Risk 38 · Moderate
Price$284.75
Model IV—
P/IV—
Limited data — see page
CELC
Celcuity Inc.
Valuation N/A
Healthcare Risk 45 · Elevated
Price$83.45
Model IV—
P/IV—
Limited data — see page
CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Valuation N/A
Healthcare Risk 28 · Moderate
Price$0.96
Model IV—
P/IV—
Market implies +92.0%/yr vs model +2.0% · above model
CENN
Cenntro Inc.
Valuation N/A
Consumer Cyclical Risk 28 · Moderate
Price$4.50
Model IV—
P/IV—
Market implies +65.2%/yr vs model +8.0% · above model
CENX
CENTURY ALUMINUM CO
Valuation N/A
Basic Materials Risk 47 · Elevated
Price$44.05
Model IV—
P/IV—
Market implies +58.5%/yr vs model +3.9% · above model
CEPF
Cantor Equity Partners IV, Inc.
Valuation N/A
Financial Services
Price$10.36
Model IV—
P/IV—
Limited data — see page
CEPO
Cantor Equity Partners I, Inc.
Valuation N/A
Financial Services Risk 27 · Moderate
Price$10.76
Model IV—
P/IV—
Market implies +55.3%/yr vs model +8.0% · above model
CEPS
Cantor Equity Partners VI, Inc.
Valuation N/A
Financial Services Risk 27 · Moderate
Price$10.35
Model IV—
P/IV—
Limited data — see page
CEPT
Cantor Equity Partners II, Inc.
Valuation N/A
Financial Services
Price$11.78
Model IV—
P/IV—
Limited data — see page
CEPV
Cantor Equity Partners V, Inc.
Valuation N/A
Financial Services
Price$10.39
Model IV—
P/IV—
Limited data — see page
CET
CENTRAL SECURITIES CORP
Valuation N/A
Unknown
Price$56.00
Model IV—
P/IV—
Limited data — see page
CEV
Eaton Vance California Municipal Income Trust
Valuation N/A
Unknown
Price$10.25
Model IV—
P/IV—
Limited data — see page
CEVA
CEVA INC
Valuation N/A
Technology Risk 42 · Elevated
Price$29.01
Model IV—
P/IV—
Market implies +57.8%/yr vs model +2.0% · above model
CFND
C1 Fund Inc.
Valuation N/A
Unknown
Price$3.18
Model IV—
P/IV—
Limited data — see page
CG
Carlyle Group Inc.
Valuation N/A
Financial Services Risk 36 · Moderate
Price$42.34
Model IV—
P/IV—
Market implies +59.5%/yr vs model +2.0% · above model
CGAU
Centerra Gold Inc.
Valuation N/A
Basic Materials Risk 27 · Moderate
Price$22.63
Model IV—
P/IV—
Limited data — see page
CGBD
Carlyle Secured Lending, Inc.
Valuation N/A
Unknown Risk 58 · Elevated
Price$11.37
Model IV—
P/IV—
Limited data — see page
CGC
Canopy Growth Corp
Valuation N/A
Healthcare Risk 53 · Elevated
Price$0.94
Model IV—
P/IV—
Limited data — see page
CGCT
Cartesian Growth Corp III
Valuation N/A
Technology
Price$5.00
Model IV—
P/IV—
Limited data — see page
CGEM
Cullinan Therapeutics, Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$20.59
Model IV—
P/IV—
Market implies +58.0%/yr vs model +15.0% · above model
CGNT
Cognyte Software Ltd.
Valuation N/A
Technology Risk 41 · Elevated
Price$8.02
Model IV—
P/IV—
Market implies +28.2%/yr vs model +3.0% · above model
CGO
CALAMOS GLOBAL TOTAL RETURN FUND
Valuation N/A
Unknown
Price$13.15
Model IV—
P/IV—
Limited data — see page
CGON
CG Oncology, Inc.
Valuation N/A
Healthcare Risk 29 · Moderate
Price$72.35
Model IV—
P/IV—
Market implies +78.2%/yr vs model +50.0% · above model
CGTL
Creative Global Technology Holdings Ltd
Valuation N/A
Industrials Risk 51 · Elevated
Price$3.86
Model IV—
P/IV—
Market implies +31.1%/yr vs model +2.0% · above model
CGTX
COGNITION THERAPEUTICS INC
Valuation N/A
Healthcare Risk 32 · Moderate
Price$0.98
Model IV—
P/IV—
Limited data — see page
CHAR
Charlton Aria Acquisition Corp
Valuation N/A
Financial Services
Price$10.96
Model IV—
P/IV—
Limited data — see page
CHARR
Charlton Aria Acquisition Corp
Valuation N/A
Financial Services
Price$0.10
Model IV—
P/IV—
Limited data — see page
CHEC
Chenghe Acquisition III Co.
Valuation N/A
Financial Services
Price$10.25
Model IV—
P/IV—
Limited data — see page
CHGG
CHEGG, INC
Valuation N/A
Consumer Defensive Risk 48 · Elevated
Price$0.73
Model IV—
P/IV—
Market implies +36.7%/yr vs model +2.0% · above model
CHI
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND
Valuation N/A
Unknown
Price$12.36
Model IV—
P/IV—
Limited data — see page
CHNR
CHINA NATURAL RESOURCES INC
Valuation N/A
Basic Materials Risk 33 · Moderate
Price$3.98
Model IV—
P/IV—
Limited data — see page
CHPG
ChampionsGate Acquisition Corp
Valuation N/A
Financial Services
Price$10.50
Model IV—
P/IV—
Limited data — see page
CHPGR
ChampionsGate Acquisition Corp
Valuation N/A
Financial Services
Price$0.19
Model IV—
P/IV—
Limited data — see page
CHRN
ChronoScale Corp
Valuation N/A
Industrials Risk 29 · Moderate
Price$19.00
Model IV—
P/IV—
Market implies +25.1%/yr vs model +3.3% · above model
CHRS
Coherus Oncology, Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$1.33
Model IV—
P/IV—
Market implies +57.0%/yr vs model +2.0% · above model
CHSCL
CHS INC
Valuation N/A
Consumer Defensive
Price$25.47
Model IV—
P/IV—
Limited data — see page
CHSCM
CHS INC
Valuation N/A
Consumer Defensive
Price$24.25
Model IV—
P/IV—
Limited data — see page
CHSCN
CHS INC
Valuation N/A
Consumer Defensive
Price$25.02
Model IV—
P/IV—
Limited data — see page
CHSCO
CHS INC
Valuation N/A
Consumer Defensive
Price$25.97
Model IV—
P/IV—
Limited data — see page
CHSCP
CHS INC
Valuation N/A
Consumer Defensive
Price$26.69
Model IV—
P/IV—
Limited data — see page
CHW
Calamos Global Dynamic Income Fund
Valuation N/A
Unknown
Price$8.43
Model IV—
P/IV—
Limited data — see page
CHY
CALAMOS CONVERTIBLE & HIGH INCOME FUND
Valuation N/A
Unknown
Price$12.56
Model IV—
P/IV—
Limited data — see page
CIB
Grupo Cibest S.A.
Valuation N/A
Financial Services Risk 62 · High
Price$101.84
Model IV—
P/IV—
Limited data — see page
CIEN
CIENA CORP
Valuation N/A
Technology Risk 40 · Elevated
Price$319.64
Model IV—
P/IV—
Market implies +35.6%/yr vs model +7.1% · above model
CIF
MFS INTERMEDIATE HIGH INCOME FUND
Valuation N/A
Unknown
Price$1.77
Model IV—
P/IV—
Limited data — see page
CIFR
Cipher Digital Inc.
Valuation N/A
Financial Services Risk 37 · Moderate
Price$15.64
Model IV—
P/IV—
Market implies +27.8%/yr vs model +50.0% · below model
CII
BlackRock Enhanced Large Cap Core Fund, Inc.
Valuation N/A
Unknown
Price$24.18
Model IV—
P/IV—
Limited data — see page
CIK
CREDIT SUISSE ASSET MANAGEMENT INCOME FUND, INC.
Valuation N/A
Unknown
Price$2.38
Model IV—
P/IV—
Limited data — see page
CING
Cingulate Inc.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$5.17
Model IV—
P/IV—
Limited data — see page
CINT
CI&T Inc
Valuation N/A
Technology Risk 31 · Moderate
Price$3.23
Model IV—
P/IV—
Limited data — see page
CITR
CitroTech Inc.
Valuation N/A
Basic Materials Risk 42 · Elevated
Price$4.92
Model IV—
P/IV—
Market implies +46.2%/yr vs model +5.0% · above model
CLBR
Colombier Acquisition Corp. III
Valuation N/A
Financial Services
Price$10.23
Model IV—
P/IV—
Limited data — see page
CLDI
Calidi Biotherapeutics, Inc.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$1.17
Model IV—
P/IV—
Limited data — see page
CLDX
Celldex Therapeutics, Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$39.18
Model IV—
P/IV—
Market implies +150.0%/yr vs model +2.0% · above model
CLGN
CollPlant Biotechnologies Ltd
Valuation N/A
Healthcare Risk 33 · Moderate
Price$3.40
Model IV—
P/IV—
Market implies +60.5%/yr vs model +2.0% · above model
CLLS
Cellectis S.A.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$3.10
Model IV—
P/IV—
Limited data — see page
CLM
Cornerstone Strategic Investment Fund, Inc.
Valuation N/A
Unknown
Price$6.58
Model IV—
P/IV—
Limited data — see page
CLMT
Calumet, Inc. /DE
Valuation N/A
Energy Risk 64 · High
Price$56.80
Model IV—
P/IV—
Market implies +37.7%/yr vs model +0.0% · above model
CLNK
Bitwise Chainlink ETF
Valuation N/A
Financial Services Risk 32 · Moderate
Price$21.12
Model IV—
P/IV—
Limited data — see page